Skip to main content

Hyperresistinemia and metabolic dysregulation: a risky crosstalk in obese breast cancer

Abstract

Breast cancer is the most common malignancy among women worldwide. There is extensive literature on the relationship between body weight and breast cancer risk but some doubts still remain about the role of adipokines per se, the role of insulin and glucose regardless of obesity, as well as the crosstalk between these players. Thus, in this study, we intend to determine the relation between body mass index (BMI), glycaemia, insulinemia, insulin-resistance, blood adipokine levels and tumour characteristics in a Portuguese group of pre- and postmenopausal overweight/obese women with breast cancer. We evaluated clinical and biochemical data in 154 participants, divided in 4 groups: (1) control with BMI <25 kg/m2, n = 29 (CT); (2) control with BMI >25 kg/m2, n = 48 (CTOb); (3) breast cancer with BMI <25 kg/m2, n = 30 (BC); and (4) breast cancer with BMI >25 kg/m2, n = 47 (BCOb). In women with breast cancer, we also performed tumour characterization. We found that BCOb present increased fasting blood glucose, insulin, resistin and monocyte chemoattractant protein 1, insulin resistance and more aggressive tumours. Notably, this profile is not correlated with BMI, proposing the involvement of other processes than adiposity. Altogether, our results suggest that glucose dysmetabolism, insulin resistance and changes in adipokine secretion, in particular resistin, may be involved in the development and progression of breast cancer in overweight/obese pre- and postmenopausal women.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

References

  1. V.G. Vogel, Epidemiology, genetics, and risk evaluation of postmenopausal women at risk of breast cancer. Menopause 15, 782–789 (2008)

    Article  PubMed  Google Scholar 

  2. A.G. Renehan, M. Tyson, M. Egger, R.F. Heller, M. Zwahlen, Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371, 569–578 (2008)

    Article  PubMed  Google Scholar 

  3. M. Dalamaga, Obesity, insulin resitance, adipocytokines and breast cancer: New biomarkers and attractive therapeutic targets. World J. Exp. Med. 20, 34–42 (2013)

    Google Scholar 

  4. D.H. Cohen, D. LeRoith, Obesity, type 2 diabetes, and cancer: the insulin and IGF connection. Endocr. Relat. Cancer 19, F27–F45 (2012)

    CAS  Article  PubMed  Google Scholar 

  5. P. Matafome, D. Santos-Silva, C.M. Sena, R. Seiça, Common mechanisms of dysfunctional adipose tissue and obesity-related cancers. Diabetes Metab. Res. Rev. 29, 285–295 (2013)

    CAS  Article  PubMed  Google Scholar 

  6. A.M. Lorincz, S. Sukumar, Molecular links between obesity and breast cancer. Endocr. Relat. Cancer 13, 279–292 (2006)

    CAS  Article  PubMed  Google Scholar 

  7. G.L. Anderson, M.L. Neuhouse, Obesity and the risk for premenopausal and postmenopausal breast cancer. Cancer Prev. Res. 5, 515–521 (2012)

    Article  Google Scholar 

  8. L. Vona-Davis, D.P. Rose, Type 2 diabetes and obesity metabolic interactions: common factors for breast cancer risk and novel approaches to prevention and therapy. Curr. Diab. Rev. 8, 116–130 (2012)

    CAS  Article  Google Scholar 

  9. D.P. Rose, L. Vona-Davis, The cellular and molecular mechanisms by which insulin influences breast cancer risk and progression. Endocr. Relat. Cancer 19, R225–R241 (2012)

    CAS  Article  PubMed  Google Scholar 

  10. A.T. Timóteo, F. Miranda, M.M. Carmo, R.C. Ferreira, Optimal cut-off value for homeostasis model assessment (HOMA) index of insulin- resistance in a population of patients admitted electively in a portuguese cardiology ward. Acta Med. Port. 27, 473–479 (2014)

    Article  PubMed  Google Scholar 

  11. American Diabetes Association, Classification and diagnosis of diabetes. Diabetes Care 38, S8–S16 (2015)

    Article  Google Scholar 

  12. F. Xue, K.B. Michels, Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. Am. J. Clin. Nutr. 86, s823–s835 (2007)

    PubMed  Google Scholar 

  13. Y. Huang, X. Cai, M. Qiu, P. Chen, H. Tang, Y. Hu, Y. Huang, Prediabetes and the risk of cancer: a meta-analysis. Diabetologia 57, 2261–2269 (2014)

    CAS  Article  PubMed  Google Scholar 

  14. N.S. Brown, R. Bicknell, Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res. 3(5), 323–327 (2001)

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  15. H.S. Moon, M. Dalamaga, S.Y. Kim, S.A. Polyzos, O.P. Hamnvik, F. Magkos, J. Paruthi, C.S. Mantzoros, Leptin’s role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals. Endocr. Rev. 34, 377–412 (2013)

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  16. R.S. Ahima, Adipose tissue as an endocrine organ. Obesity 14(5), 242S–249S (2006)

    CAS  Article  PubMed  Google Scholar 

  17. N.S. Brown, R. Bicknell, Hypoxia and oxidative stress in breast cancer: Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res. 3, 323–327 (2001)

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  18. C.A. Sun, M.H. Wu, C.H. Chu, Y.C. Chou, G.C. Hsu, T. Yang, YuCP Chou Wy, J.C. Yu, Adipocytokine resistin and breast cancer. Breast Cancer Res. Treat. 123, 869–876 (2010)

    CAS  Article  PubMed  Google Scholar 

  19. M. Dalamaga, Resistin as a biomarker linking obesity and inflammation to cancer: potential clinical perspectives. Biomark. Med. 8(1), 107–118 (2014)

    CAS  Article  PubMed  Google Scholar 

  20. Y.C. Lee, Y.J. Chen, C.W. Chun, S. Lo, M.F. Hou, S.S. Yuan, Resistin expression in breast cancer tissue as a marker of prognosis and hormone therapy stratification. Gynecol. Oncol. 125, 742–750 (2012)

    CAS  Article  PubMed  Google Scholar 

  21. M. Dalamaga, K. Karmaniolas, E. Papadavid, N. Pelekanos, G. Sotiropoulos, A. Lekka, Hyperresistinemia is associated with postmenopausal breast cancer. Menopause 20, 845–851 (2013)

    Article  PubMed  Google Scholar 

  22. M. Dalamaga, G. Sotiropoulos, K. Karmaniolas, N. Pelekanos, E. Papadavid, A. Lekka, Serum resistin: a biomarker of breast cancer in postmenopausal women? Association with clinicopathological characteristics, tumor markers, inflammatory and metabolic parameters. Clin. Biochem. 46, 584–590 (2013)

    CAS  Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Joana Crisóstomo.

Ethics declarations

Conflicts of interest

There are no potential conflicts of interest.

Funding

This work was funded with a Grant (PTDC/SAU-MET/121133/2010) from the Portuguese Foundation of Science and Technology.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Crisóstomo, J., Matafome, P., Santos-Silva, D. et al. Hyperresistinemia and metabolic dysregulation: a risky crosstalk in obese breast cancer. Endocrine 53, 433–442 (2016). https://doi.org/10.1007/s12020-016-0893-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-016-0893-x

Keywords

  • Breast cancer
  • Resistin
  • Insulin
  • Glucose